Technical Analysis for CERC - Cerecor Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical CERC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| NR7 | Range Contraction | -1.76% | |
| Wide Bands | Range Expansion | -1.76% | |
| Down 3 Days in a Row | Weakness | -1.76% | |
| 50 DMA Resistance | Bearish | -3.75% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 10/28/2019
- Sector: Healthcare
- Industry: Biotechnology
Cerecor, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company has a portfolio of clinical and preclinical compounds, such as CERC-301, CERC-501, and CERC-406. It develops CERC-301 that is in Phase II development stage as an oral, adjunctive antidepressant for the treatment of patients with major depressive disorder (MDD); CERC-501, which is in Phase II development, for co-occurring psychiatric and substance use disorders; and CERC-406 that is its preclinical lead candidate that inhibit catechol-O-methyltransferase within the brain, as well as anticipates developing CERC-406 for the treatment of residual cognitive impairment symptoms in patients with MDD. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor, Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.
Chemistry Biopharmaceutical Disorders Organic Chemistry Major Depressive Disorder Depression Pyrrolidines Antidepressants Piperidines Nmda Receptor Antagonists
Chemistry Biopharmaceutical Disorders Organic Chemistry Major Depressive Disorder Depression Pyrrolidines Antidepressants Piperidines Nmda Receptor Antagonists
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more CERC news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 7.65 |
| 52 Week Low | 2.71 |
| Average Volume | 81,639 |
| 200-Day Moving Average | 4.672 |
| 50-Day Moving Average | 3.7266 |
| 20-Day Moving Average | 3.2935 |
| 10-Day Moving Average | 3.404 |
| Average True Range | 0.3248 |
| ADX | 18.89 |
| +DI | 24.8499 |
| -DI | 18.49 |
| Chandelier Exit (Long, 3 ATRs ) | 3.2456 |
| Chandelier Exit (Short, 3 ATRs ) | 3.8844 |
| Upper Bollinger Band | 3.7371 |
| Lower Bollinger Band | 2.8499 |
| Percent B (%b) | 0.55 |
| BandWidth | 26.937908 |
| MACD Line | -0.0702 |
| MACD Signal Line | -0.1195 |
| MACD Histogram | 0.0493 |
| Fundamentals | Value |
|---|---|
| Market Cap | 87.01 Million |
| Num Shares | 26.1 Million |
| EPS | -1.12 |
| Price-to-Earnings (P/E) Ratio | -2.98 |
| Price-to-Sales | 24.44 |
| Price-to-Book | 4.41 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.63 | ||||
| Resistance 3 (R3) | 3.63 | 3.54 | 3.58 | ||
| Resistance 2 (R2) | 3.54 | 3.47 | 3.54 | 3.56 | |
| Resistance 1 (R1) | 3.44 | 3.42 | 3.40 | 3.44 | 3.55 |
| Pivot Point | 3.35 | 3.35 | 3.33 | 3.35 | 3.35 |
| Support 1 (S1) | 3.25 | 3.28 | 3.21 | 3.25 | 3.13 |
| Support 2 (S2) | 3.16 | 3.23 | 3.16 | 3.12 | |
| Support 3 (S3) | 3.06 | 3.16 | 3.10 | ||
| Support 4 (S4) | 3.06 |
